Achieve life sciences announces publication of cytisinicline phase 3 orca-2 smoking cessation trial in journal of the american medical association (jama)

Cytisinicline 6- and 12-week dosing schedules, with behavioral support, demonstrated “smoking cessation efficacy and excellent tolerability”
ACHV Ratings Summary
ACHV Quant Ranking